Loading stock data…
MLTX
$17.80-0.20 (-1.11%)
After Hours$17.71-0.09 (-0.51%)· Last close Jun 9
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MoonLake Immunotherapeutics in the Healthcare sector is trading at $17.80. Wall Street consensus targets $27.62 (13 analysts), implying a +55.1% move over the next 12 months. The stock is currently 72% below its 52-week high of $62.75, remaining 11.5% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +55.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$17.80
Potential Downside
0%
Whystock Fair Value$17.80
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of in...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-101.20%
Volume
Today's trading volume
933,696
Recent News
Why Did MLTX Stock Rise After-Hours Today?
Investors are awaiting multiple Phase 3 readouts in the second half of the year, including Vela, Izar and Vela-Teen trial results.
MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned?
This clinical-stage biotech focused on inflammatory diseases reported a notable insider sale amid a year of sharp share price declines.
MoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA Progress
We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds. MoonLake Immunotherapeutics (NASDAQ:MLTX) is among the best immunology stocks. TheFly reported on May 11 that H.C. Wainwright increased its price objective on MLTX to $45 from $40 while reaffirming a Buy rating on the stock. The revision followed […]
MoonLake Immunotherapeutics (MLTX) Is Up 7.3% After FDA Aligns on Sonelokimab BLA Pathway
MoonLake Immunotherapeutics reported a first‑quarter 2026 net loss of US$69.71 million, while securing alignment with the U.S. FDA on a planned September 2026 Biologics License Application for sonelokimab in hidradenitis suppurativa, including adult and adolescent patients. This FDA feedback effectively completes the pre‑BLA process and supports a proposed label anchored on what MoonLake describes as best‑in‑class HiSCR75 response data in hidradenitis suppurativa. We will now examine how...
MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket
Shares of MoonLake Immunotherapeutics bounded higher Monday after the biotech said it met with the Food and Drug Administration in April.